Pfizer Inc. - Product Pipeline Review - 2016

  • ID: 3665219
  • Company Profile
  • 419 pages
  • Global Markets Direct
  • Pfizer Inc.
1 of 4
Pfizer Inc. - Product Pipeline Review - 2016

Summary

‘Pfizer Inc. - Product Pipeline Review - 2016’, provides an overview of the Pfizer Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Pfizer Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Pfizer Inc.
- The report provides overview of Pfizer Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Pfizer Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Pfizer Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Pfizer Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pfizer Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pfizer Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Pfizer Inc. Snapshot

Pfizer Inc. Overview

Key Information

Key Facts

Pfizer Inc. - Research and Development Overview

Key Therapeutic Areas

Pfizer Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Pfizer Inc. - Pipeline Products Glance

Pfizer Inc. - Late Stage Pipeline Products

Pfizer Inc. - Clinical Stage Pipeline Products

Pfizer Inc. - Early Stage Pipeline Products

Pfizer Inc. - Drug Profiles

(naltrexone hydrochloride + oxycodone hydrochloride) ER

crizotinib

palbociclib

tofacitinib

epoetin zeta

gemtuzumab ozogamicin

tafamidis meglumine

(ertugliflozin + metformin hydrochloride)

(ertugliflozin + sitagliptin phosphate)

adalimumab biosimilar

axitinib

bevacizumab biosimilar

bococizumab

bosutinib

celecoxib

dacomitinib

ertugliflozin

gosogliptin

infliximab biosimilar

inotuzumab ozogamicin

meningococcal [serotype B] vaccine

pregabalin

pregabalin CR

rituximab biosimilar

rivipansel sodium

sildenafil citrate

sunitinib malate

tanezumab

trastuzumab biosimilar

ziprasidone mesylate

ascrinvacumab

Dekavil

domagrozumab

fosdagrocorat

gedatolisib

glasdegib

lorlatinib

Nimenrix

nirogacestat

PF-00489791

PF-00547659

PF-02545920

PF-04236921

PF-04457845

PF-05089771

PF-06290510

PF-06291874

PF-06425090

PF-06838435

ponezumab

temsirolimus

agatolimod sodium

pegfilgrastim

PF-06747775

filgrastim

HIV vaccine

PF-04136309

PF-04447943

PF-04518600

PF-04958242

PF-05082566

PF-05206388

PF-05230907

PF-05251749

PF-05402536

PF-06266047

PF-06273340

PF-06282999

PF-06293620

PF-06342674

PF-06412562

PF-06413367

PF-06427878

PF-06444752

PF-06444753

PF-06480605

PF-06647020

PF-06647263

PF-06648671

PF-06649751

PF-06650808

PF-06650833

PF-06651600

PF-06664178

PF-06669571

PF-06678552

PF-06700841

PF-06741086

PF-06751979

PF-06753512

PF-06755990

PF-06755992

PF-06801591

PF-06815345

Biologics for Undisclosed Indication

Biologics to Target PCSK-9 for Hypercholesterolemia

CE-355621

Drugs for Duchenne Muscular Dystrophy

GIBH-1008

GIBH-1010

GIBH-1018

GL-2045

HSD-621

J-17

Monoclonal Antibodies for Solid Tumor

MOR-8457

NIC7-DT

PD-0360324

PF-01247324

PF-06380101

PF-06447475

PF-06671008

PF-1355

PF-3845

PF-4989216

PF-5006739

PNU-120596

Proteins to Agonize MC4R for Obesity

RBT-301

Small Molecule 1 for Solid Tumors

Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor

Small Molecule to Inhibit IDO-1 for Oncology

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections

Small Molecule to Inhibit TDO-2 for Oncology

Small Molecule to Modulate Androgen Receptor for Muscle Disorders

Small Molecules to Activate CFTR for Cystic Fibrosis

Small Molecules to Inhibit Mps1 for Breast Cancer

Small Molecules to Inhibit NMT for Malaria

Small Molecules to Inhibit PDE2 for Osteoarthritis Pain

Vaccine 2 for Undisclosed Indication

Monoclonal Antibody Conjugates for Oncology

PF-00190434

PF-04445597

PF-46396

PPD-1

Small Molecule to Agonize LXR for Inflammation

Small Molecule to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation

Small Molecule to Antagonize Ghrelin Receptor for Alcoholism

Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia

Small Molecule to Inhibit Acetyl-CoA Carboxylase for Metabolic Disorders

Small Molecule to Inhibit EZH2 for Oncology

Small Molecule to Inhibit MMP13 for Osteoarthritis

Small Molecule to Inhibit NS5A for HCV

Small Molecule to Inhibit PI3K Alpha and mTOR for Oncology

Small Molecule to Inhibit Pin1 for Oncology

Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome

Small Molecules for Inflammatory and Orphan Diseases

Small Molecules for Obesity and Diabetes

Small Molecules for Ulcerative Colitis and Crohn's Disease

Small Molecules to Agonize A1 Adenosine Receptor

Small Molecules to Agonize ADRB2 and Antagonize CHRM3 for COPD

Pfizer Inc. - Pipeline Analysis

Pfizer Inc. - Pipeline Products by Target

Pfizer Inc. - Pipeline Products by Route of Administration

Pfizer Inc. - Pipeline Products by Molecule Type

Pfizer Inc. - Pipeline Products by Mechanism of Action

Pfizer Inc. - Recent Pipeline Updates

Pfizer Inc. - Dormant Projects

Pfizer Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Pfizer Inc. - Company Statement

Pfizer Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Pfizer Inc., Key Information

Pfizer Inc., Key Facts

Pfizer Inc. - Pipeline by Indication, 2016

Pfizer Inc. - Pipeline by Stage of Development, 2016

Pfizer Inc. - Monotherapy Products in Pipeline, 2016

Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2016

Pfizer Inc. - Partnered Products in Pipeline, 2016

Pfizer Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Pfizer Inc. - Out-Licensed Products in Pipeline, 2016

Pfizer Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Pfizer Inc. - Pre-Registration, 2016

Pfizer Inc. - Filing rejected/Withdrawn, 2016

Pfizer Inc. - Phase III, 2016

Pfizer Inc. - Phase II, 2016

Pfizer Inc. - Phase I, 2016

Pfizer Inc. - Preclinical, 2016

Pfizer Inc. - Discovery, 2016

Pfizer Inc. - Pipeline by Target, 2016

Pfizer Inc. - Pipeline by Route of Administration, 2016

Pfizer Inc. - Pipeline by Molecule Type, 2016

Pfizer Inc. - Pipeline Products by Mechanism of Action, 2016

Pfizer Inc. - Recent Pipeline Updates, 2016

Pfizer Inc. - Dormant Developmental Projects,2016

Pfizer Inc. - Discontinued Pipeline Products, 2016

Pfizer Inc., Other Locations

Pfizer Inc., Subsidiaries

List of Figures

Pfizer Inc. - Pipeline by Top 10 Indication, 2016

Pfizer Inc. - Pipeline by Stage of Development, 2016

Pfizer Inc. - Monotherapy Products in Pipeline, 2016

Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2016

Pfizer Inc. - Partnered Products in Pipeline, 2016

Pfizer Inc. - Out-Licensed Products in Pipeline, 2016

Pfizer Inc. - Pipeline by Top 10 Target, 2016

Pfizer Inc. - Pipeline by Route of Administration, 2016

Pfizer Inc. - Pipeline by Top 10 Molecule Type, 2016

Pfizer Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll